Polyquaternium-1

• Description:

  Polyquaternium-1 (Polidronium chloride; PQ-1) is an antimicrobial preservative and an activator of NF-κB. Polyquaternium-1 targets bacterial cell membranes, commonly used in ophthalmic surgery. Polyquaternium-1 adsorbs to the surface of microbial membranes through its polycationic properties, destroying membrane integrity and inducing potassium ion leakage, leading to bacterial death. Polyquaternium-1 exerts antimicrobial effects at a concentration of 0.001% and has low toxicity to mammalian cells. Polyquaternium-1 can be used to prepare products such as glaucoma eye drops (Travoprost preparations containing PQ-1), artificial tears, and contact lens solutions to reduce the ocular surface toxicity of traditional preservatives such as benzalkonium chloride (HY-B2232) [1][2][3].

• Product Name Alternative:

  Polidronium (chloride)

• UNSPSC:

  12352211

• Hazard Statement:

  H315, H319, H335

• Target:

  Biochemical Assay Reagents

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/polyquaternium-1.html

• Purity:

  99.0

• Solubility:

  H2O : 50 mg/mL (ultrasonic)

• Smiles:

  OCC[N+](CCO)(C/C=C/C[N+](C)(C/C=C/C[N+](CCO)(CCO)CCO)C)CCO.[3Cl-].[n]

• Molecular Formula:

  (C6H12N) nC16H36N2O6.3Cl

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Paimela T, et al. The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. Mol Vis. 2012;18:1189-96. Epub 2012 May 6.|[2]Rolando M, et, al. Ophthalmic preservatives: focus on polyquaternium-1. Expert Opin Drug Deliv. 2011 Nov;8 (11) :1425-38.|[3]Mohamed YH, et al. Acute Corneal Toxicity of Combined Antiglaucoma Topical Eyedrops. Curr Eye Res. 2016 Oct;41 (10) :1326-1330.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 4

• CAS Number:

  75345-27-6